Cullinan Therapeutics presented initial Phase 1 clinical data for CLN-978, a CD19xCD3 T cell engager, showing clinical benefits including remissions in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The drug demonstrated deep, dose-dependent B cell depletion in blood and tissues with a favorable safety profile up to 30 µg doses. These results highlight CLN-978's potential as a disease-modifying treatment for challenging autoimmune diseases, with further multi-dose studies underway. Cullinan plans to advance global clinical development rapidly to bring this new therapy to patients.
U.S. spot Bitcoin ETFs experienced $325.7 million in net outflows on June 5, led by BlackRock’s IBIT with $213.7 million withdrawn, coinciding with Bitcoin’s price falling below the key $60,000 support level to around $59,100. Analysts link the outfl...
Bitcoin has dropped below its 200-week moving average and key support levels, including the February lows, signaling continued bearish control. However, it remains near a significant long-term rising trendline connecting past cycle lows, suggesting a...
Russia's central bank will restrict non-qualified retail investors to trading only Bitcoin, Ethereum, and USDT, citing high volatility and risk concerns. An annual investment limit of about 300,000 rubles per broker will apply to protect investors fr...
Arthur Hayes, co-founder of BitMEX, sold his entire Worldcoin (WLD) position on June 6 after initially supporting the AI-linked token. He had previously exited other altcoins like HYPE, NEAR, and ZEC within days, citing rising market volatility and m...
MicroStrategy's executive chairman Michael Saylor has dismissed rumors of an imminent margin call on the company's 713,000 Bitcoin holdings, despite Bitcoin trading below the average acquisition cost of about $75,699 per coin. The company’s debt is m...
